Clever gene construct combats metabolic syndrome

December 18, 2012 by Peter Rüegg
Tastes nice but is unhealthy: anyone who makes a habit of eating fast food and does not do enough exercise can expect various symptoms of metabolic syndrome, such as high blood pressure, obesity and diabetes. Credit: SteFou!/Flickr

(Medical Xpress)—Researchers under ETH-Zurich professor Martin Fussenegger have created a new genetic network that could cure the various symptoms of so-called metabolic syndrome in one fell swoop. It already works in mice.

Too much of the wrong food and not enough exercise: sooner or later, an increasing number of people in industrial nations pay the price for their lifestyle. High , changed blood fat values, as a precursor to diabetes, and abdominal fat are characteristic of metabolic syndrome, the 'killer of the twenty-first century'. After all, it is the major risk factor for the development of coronary heart diseases. Today, many more people die of cardiovascular diseases worldwide than from cancer.

Until now, however, there has not been a holistic therapy for metabolic syndrome. Medicine diagnoses and treats every single symptom of metabolic syndrome separately. "However, all these diseases are linked," says ETH-Zurich professor Martin Fussenegger from the Department of Biosystems in Basel. His research group has now found an approach that could treat all the symptoms of metabolic syndrome at once.

Antihypertensive drug triggers cascade

The biotechnologists have constructed a synthetic signaling cascade from different that can be triggered with the antihypertensive drug guanabenz and controlled based on the dosage. After the start signal, a is set in motion in the cell and culminates with the production of a "super hormone" in the . This includes GLP1, which is connected to leptin via a molecular bridge. GLP1 reduces the ; leptin inhibits the feeling of hunger and thus plays a key role in regulating the .

The combination of the drug guanabenz, which has already been approved for clinical use, and the 'super hormone' produced by the synthetic signal cures all three key diseases associated with metabolic syndrome at the same time.

The researchers tested their network in a model experiment using diabetic, obese mice suffering from . The animals lack the satiety hormone leptin so are always hungry and eat more than is good for them. The ETH-Zurich biotechnologists inserted an implant with ten million cells, each of which contained the synthetic signalling pathway, into the mice.

Construct successful in mice

The animals responded very well to the dose of guanabenz: the GLP1 and leptin concentration rose dramatically and twenty-four hours after the drug was dispensed insulin secretion also increased on account of the GLP1 content. After only three days, the level of cholesterol and other free fatty acids in the blood dropped – a good sign that the animals were beginning to recover from metabolic syndrome. Free guanabenz even lowered the blood pressure, too.

"This application is also realistic for the treatment of metabolic syndrome in humans," Fussenegger predicts. GLP1 is already administered as an alternative to insulin in the battle against diabetes. Leptin, on the other hand, would have to be substituted with another hormone that has a similar effect. "Leptin has failed to live up to its hopes as a therapeutic agent against obesity, as obese patients have sufficient leptin but have grown resistant to it," stresses the ETH-Zurich professor. However, he is confident that they can incorporate an alternative satiety hormone into their network. They merely used leptin to demonstrate the principle. It works perfectly well in mice.

In planning and constructing this network, the researchers were able to fall back on the Fussenegger group's existing expertise. The ingenious scientists had already assembled gene networks for diabetes or gout with similar biological components, the properties of which are renowned. "But we only discovered that the antihypertensive drug guanabenz can be used as a start button by chance," says the ETH-Zurich professor from Basel.

Even though he is convinced that a gene construct designed in this way could treat with its array of symptoms, for the time being Fussenegger is reluctant to make any promises as to when a corresponding product might hit the market.

Explore further: Metabolic syndrome makes a difference in hormone therapy risk

More information: Ye H, Charpin-El Hamri G, Zwicky K, Christen M, Folcher M, Fussenegger M. Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. PNAS online, doi: 10.1073/pnas.1216801110

Related Stories

Metabolic syndrome makes a difference in hormone therapy risk

October 30, 2012

A new analysis of the Women's Health Initiative (WHI) trials show that women who had metabolic syndrome before they started hormone therapy had a greatly increased risk of heart attack or dying of heart disease. Women who ...

Recommended for you

An accessible approach to making a mini-brain

October 1, 2015

If you need a working miniature brain—say for drug testing, to test neural tissue transplants, or to experiment with how stem cells work—a new paper describes how to build one with what the Brown University authors say ...

Tension helps heart cells develop normally in the lab

October 1, 2015

The heart is never quite at rest, and it turns out that even in a lab heart cells need a little of that tension. Without something to pull against, heart cells grown from stem cells in a lab dish fail to develop normally.

Dormant viral genes may awaken to cause ALS

September 30, 2015

Scientists at the National Institutes of Health discovered that reactivation of ancient viral genes embedded in the human genome may cause the destruction of neurons in some forms of amyotrophic lateral sclerosis (ALS). The ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (1) Dec 18, 2012
Do the epigenetic effects of the drug take into account any of the 4.5 million other DNA switches that might be altered via the same pathway? For example, could side effects be controlled with another drug like the one that's being developed for depression, which reportedly has no ketamine-like side effects? "GLYX-13, an NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects'

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.